

RealRate

PHARMACEUTICAL 2020











PHARMACEUTICAL 2020

MARIZYME INC. Rank 6 of 358



The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 254% points. The greatest weakness of MARIZYME INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 330%, being 294% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	0.090
Cost of Goods Sold	0
Intangible Assets	28,613
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	947
Other Liabilities	270
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	111

Output Variable	Value in 1000 USD
Assets	28,613
Liabilities	270
Expenses	1,058
Revenues	0
Stockholders Equity	28,343
Net Income	-1,058
Comprehensive Net Income	-1,058
Economic Capital Ratio	330%

